The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 5, Pages e62736
Publisher
Public Library of Science (PLoS)
Online
2013-05-11
DOI
10.1371/journal.pone.0062736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone
- (2013) Louise Moist ANNALS OF INTERNAL MEDICINE
- Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease
- (2012) Sławomir Lizakowski et al. AMERICAN JOURNAL OF HYPERTENSION
- Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview
- (2012) Fabio Angeli et al. Expert Opinion On Drug Safety
- Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
- (2012) Hans-Henrik Parving et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease
- (2012) Szu-yuan Li et al. BMC Nephrology
- Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy
- (2011) F. Persson et al. Clinical Journal of the American Society of Nephrology
- Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study
- (2011) S. C. W. Tang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
- (2010) F. Persson et al. DIABETES CARE
- Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
- (2010) Mihai Gheorghiade et al. EUROPEAN JOURNAL OF HEART FAILURE
- Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS
- (2010) Henry Krum et al. EUROPEAN JOURNAL OF HEART FAILURE
- The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility
- (2009) Ian S.D. Roberts et al. KIDNEY INTERNATIONAL
- The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification
- (2009) Daniel C. Cattran et al. KIDNEY INTERNATIONAL
- Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
- (2008) F. Persson et al. KIDNEY INTERNATIONAL
- Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
- (2008) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now